We also demonstrate that the novel PARP inhibitor Talazoparib induces DNA damage and subsequent apoptosis when used as monotherapy after sustained exposition in BLCA cell lines and three-dimensional xenograft models, providing evidence that the reported anticancer activity of Talazoparib should also apply to BLCA. This evidence concerns the gene PARP1 and bladder transitional cell carcinoma.